Kiora Pharmaceuticals, Inc. - KPRX
About Gravity Analytica
Recent News
- 05.05.2025 - Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
- 03.12.2025 - Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
- 02.13.2025 - Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
- 02.11.2025 - Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Recent Filings
- 04.30.2025 - DEF 14A Other definitive proxy statements
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 Statement of changes in beneficial ownership of securities